Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets: 2016-2025

Historic Other Non-Current Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $57.9 million.

  • Ultragenyx Pharmaceutical's Other Non-Current Assets rose 7.40% to $57.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.9 million, marking a year-over-year increase of 7.40%. This contributed to the annual value of $62.7 million for FY2024, which is 8.66% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Other Non-Current Assets of $57.9 million as of Q3 2025, which was down 3.76% from $60.1 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Other Non-Current Assets high stood at $62.7 million for Q4 2024, and its period low was $8.9 million during Q1 2021.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Other Non-Current Assets value was $57.7 million (recorded in 2023), while the average stood at $49.5 million.
  • Data for Ultragenyx Pharmaceutical's Other Non-Current Assets shows a peak YoY spiked of 382.22% (in 2021) over the last 5 years.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other Non-Current Assets (Quarterly) stood at $20.6 million in 2021, then spiked by 135.13% to $48.3 million in 2022, then climbed by 19.34% to $57.7 million in 2023, then climbed by 8.66% to $62.7 million in 2024, then increased by 7.40% to $57.9 million in 2025.
  • Its last three reported values are $57.9 million in Q3 2025, $60.1 million for Q2 2025, and $62.4 million during Q1 2025.